You're asking about a very specific chemical compound, **[4-amino-3-(4-methylphenyl)-2-sulfanylidene-5-thiazolyl]-(4-morpholinyl)methanone**. It's a complex molecule with a long chemical name, and it's not something that's widely known or studied.
To understand its potential importance, we need to break it down and consider its structural features:
* **Thiazole Ring:** The compound contains a thiazole ring, which is a heterocyclic ring system with nitrogen and sulfur atoms. Thiazoles are found in many biologically active compounds, including antibiotics, antifungals, and anti-inflammatory agents.
* **Aromatic Groups:** It has an aromatic ring (phenyl, containing a methyl group) attached to the thiazole ring. Aromatic systems are often associated with biological activity.
* **Sulfanilide Moiety:** The sulfanylidene part hints at a sulfanilide group, which is a known pharmacophore (structure associated with biological activity) found in many drugs, like sulfonamides.
* **Amide Linker:** The compound has an amide linkage, which is a common structural feature in many drugs and is involved in binding to biological targets.
**However, without additional information, it's impossible to say why this specific compound is important for research.** Here's why:
* **It's not a known drug or research chemical:** It's highly likely that this molecule has not been synthesized or studied extensively. It might be a hypothetical compound, an intermediate in a chemical synthesis, or a specific target for a particular research project.
* **We need context:** To understand its significance, we need to know the research context:
* **What is the intended application?** Is it being investigated for potential medicinal properties, as a catalyst, or for other uses?
* **Who is researching it?** Is it a pharmaceutical company, a research lab, or an individual scientist?
**To learn more, you would need to:**
1. **Find the research paper or publication where this compound is mentioned.** The name of the compound should be used as a search term in scientific databases like PubMed, Scopus, or Google Scholar.
2. **Reach out to the researchers involved in the project.** They would be the best source of information about the importance and rationale behind investigating this specific compound.
Without more context, it's difficult to determine the significance of this particular molecule.
ID Source | ID |
---|---|
PubMed CID | 891289 |
CHEMBL ID | 1391676 |
CHEBI ID | 117165 |
Synonym |
---|
OPREA1_267128 |
morpholine, 4-((4-amino-2,3-dihydro-3-(4-methylphenyl)-2-thioxo-5-thiazolyl)carbonyl)- |
4-((4-amino-2,3-dihydro-3-(4-methylphenyl)-2-thioxo-5-thiazolyl)carbonyl)morpholine |
brn 1223645 |
smr000072798 |
MLS000089115 , |
4-amino-3-(4-methylphenyl)-5-(4-morpholinylcarbonyl)-1,3-thiazole-2(3h)-thione |
CHEBI:117165 |
MLS-0046401.0001 |
[4-amino-3-(4-methylphenyl)-2-thioxo-2,3-dihydro-1,3-thiazol-5-yl](morpholin-4-yl)methanone |
STK877254 |
AKOS000348763 |
57037-01-1 |
[4-amino-3-(4-methylphenyl)-2-sulfanylidene-1,3-thiazol-5-yl]-morpholin-4-ylmethanone |
HMS2461K16 |
(4-amino-2-thioxo-3-(p-tolyl)-2,3-dihydrothiazol-5-yl)(morpholino)methanone |
F3222-3036 |
4-amino-3-(4-methylphenyl)-5-(morpholine-4-carbonyl)-2,3-dihydro-1,3-thiazole-2-thione |
[4-amino-3-(4-methylphenyl)-2-sulfanylidene-5-thiazolyl]-(4-morpholinyl)methanone |
[4-azanyl-3-(4-methylphenyl)-2-sulfanylidene-1,3-thiazol-5-yl]-morpholin-4-yl-methanone |
[4-amino-3-(p-tolyl)-2-thioxo-4-thiazolin-5-yl]-morpholino-methanone |
bdbm34472 |
cid_891289 |
CHEMBL1391676 |
Q27203795 |
SR-01000263314-1 |
sr-01000263314 |
Z204242748 |
DTXSID20972518 |
[4-amino-3-(4-methylphenyl)-2-sulfanylidene-2,3-dihydro-1,3-thiazol-5-yl](morpholin-4-yl)methanone |
Class | Description |
---|---|
morpholines | Any compound containing morpholine as part of its structure. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 19.9526 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 5.7925 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 5.7925 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 56.2341 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 19.9526 | 0.0126 | 10.6917 | 88.5700 | AID887 |
TDP1 protein | Homo sapiens (human) | Potency | 11.2202 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 3.1623 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 79.4328 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 0.7079 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 3.9811 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0018 | 15.6638 | 39.8107 | AID894 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 2.8184 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 15.0030 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 5.0119 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.4000 | 9.3610 | 90.0000 | AID2684 |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.1000 | 12.7265 | 63.0000 | AID2678 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |